Novo Nordisk says Ozempic shows lower risk of cardiovascular events compared to Eli Lilly's Mounjaro
29/09/2026 11:28
Novo Nordisk says Ozempic shows lower risk of cardiovascular events compared to Eli Lilly's Mounjaro COPENHAGEN, Sept 29 (Reuters) - Novo Nordisk NOVOb.CO said on Tuesday a real-world study found that adults with type 2 diabetes who escalated their dose of diabetes drug Ozempic to 2 milligrams (mg) from 1 mg had a lower risk of major cardiovascular events compared to those who switched to Eli Lilly's Mounjaro.
(Reporting by Louise Rasmussen, editing by Stine Jacobsen)
((Louisebreusch.rasmussen@tr.com; +45 21 27 97 79;))
Recent news on Eli Lilly and
See all newsUS stocks weekly: Spooky
Street View: Next-generation drugs bolster Lilly's growth outlook
US STOCKS-Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
US STOCKS-Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
US STOCKS-Wall Street slides as Alphabet revenue miss revives AI capex jitters